Vanda Pharmaceuticals
VNDA
Vanda Pharmaceuticals (VNDA) news
Recent news
Vanda Pharmaceuticals - imsidolimab BLA for GPP under FDA review with target action date December 12, 2026
AInvest Wire · Jul 16, 2026Vanda Pharmaceuticals: EMA positive opinion for orphan drug designation of imsidolimab for generalized pustular psoriasis - A
AInvest Wire · Jul 16, 2026Vanda Pharmaceuticals Inc: Advancing development of its investigational therapy for CMT2S
AInvest Wire · Jul 7, 2026Vanda Pharmaceuticals reports FDA rare pediatric disease
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has been designated by the U.S. Food and Drug Administration (FDA) for a rare pediatric disease, according to a recent announcement. The designation is part of the FDA’s Rare Pediatric Disease Priority Review Voucher Program, which aims to encourage the…
AInvest Wire · Jul 7, 2026Vanda Pharmaceuticals reports orphan drug designation in Japan
AInvest Wire · May 27, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.